How did Corcept Therapeutics' revenue and expenses trend in Q4 2024?

Corcept Therapeutics experienced a decline in revenue and an increase in expenses during Q4 2024 compared to the previous quarter.

1. **Revenue Trend**: The company's revenue decreased by approximately 4.33% to $675.04 million in Q4 2024, down from the previous quarter's revenue of $493.15 million. This indicates a contraction in sales and a potential impact on business performance.
2. **Expense Trend**: The Cost of Goods Sold remained at $2.96 million, which did not change significantly. However, the Selling, General, and Administrative Expenses increased to $83.37 million, up from the previous quarter's $70.3 million. This suggests that despite the revenue decline, operational costs have risen, potentially affecting profitability.
3. **Net Income**: The company reported a Net Income of $30.75 million in Q4 2024, which is a notable figure considering the revenue decline. This indicates that Corcept Therapeutics was able to maintain profitability despite the challenges in revenue growth.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|CORT|CORT.O|Corcept Therapeutics|20240101-2024|Product|6.7504E8|186|
|CORT|CORT.O|Corcept Therapeutics|20240101-2024|Product|4.9315E8|186|
|CORT|CORT.O|Corcept Therapeutics|20240101-2024|Product|3.10604E8|186|
|CORT|CORT.O|Corcept Therapeutics|20240101-2024|Product|1.46808E8|186|
|CORT|CORT.O|Corcept Therapeutics|20240101-2024|Product|1.46808E8|186|

|code|Ticker|Name|Date|Cost of Goods Sold|R&D Expenses|Net Income|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|---|
|CORT|CORT.O|Corcept Therapeutics|2024 Q1|2535000|5.8505E7|2.7762E7||186|
|CORT|CORT.O|Corcept Therapeutics|2024 Q2|2524000|5.8745E7|3.5488E7||186|
|CORT|CORT.O|Corcept Therapeutics|2024 Q3|2867000|5.9336E7|4.7213E7||186|
|CORT|CORT.O|Corcept Therapeutics|2024 Q4|2956000|7.03E7|3.0746E7||186|